Neurocrine Biosciences | NBIX - Cost Of Sales


Neurocrine Biosciences reported $13.8M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
AbbVie USD 4.22B 329M Mar/2026
Acadia Pharmaceuticals USD 24.79M 1.43M Mar/2026
Agios Pharmaceuticals USD 1.32M 560K Mar/2026
ALKERMES USD 73.25M 27.04M Mar/2026
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amgen USD 1.6B 187M Mar/2026
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Cytokinetics USD 160K 104.24M Mar/2026
Exelixis USD 19.95M 6.53M Mar/2026
Gilead Sciences USD 1.44B 174M Mar/2026
Halozyme Therapeutics USD 108.75M 6.6M Mar/2026
Incyte USD 104.5M 16.68M Mar/2026
Ionis Pharmaceuticals USD 3M 5M Mar/2026
Nektar Therapeutics USD 4.43M 5.3M Sep/2024
Neurocrine Biosciences USD 13.8M 3.8M Mar/2026
Pfizer USD 4.59B 1.7B Mar/2026
Prothena USD 28.94M 11.58M Sep/2025
Regeneron Pharmaceuticals USD 669.4M 84.8M Mar/2026
Repligen USD 85.97M 8.11M Mar/2026
Rigel Pharmaceuticals USD 8.03M 5.22M Sep/2024
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
Teva Pharmaceutical Industries USD 2.01B 46M Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026
Xoma 116K 112.7K Jun/2024